STAAR Surgical expects first-quarter net sales to exceed $90 million, more than doubling from last year, driven mainly by growth in China and the Americas. Disney plans to cut about 1,000 marketing jobs as part of a strategic overhaul under new CEO Josh D'Amaro to improve profit margins. Meanwhile, low-cost generic versions of semaglutide in India are challenging market leaders Novo Nordisk and Eli Lilly, signaling potential global impacts as patents expire. These developments highlight shifts in healthcare and entertainment sectors with implications for investors.
Capital Link has published its Q2 2026 Quarterly Shipping Insights report, featuring exclusive interviews with senior executives from major shipping sectors including Container, Dry Bulk, LNG, LPG, and Tankers. The 132-page report covers critical the...
Disney continues to leverage its strong intellectual property portfolio, with steady revenue growth and robust cash generation despite operational and debt challenges. The success of Toy Story 5, which earned $780 million at the box office, highlight...
